ARTHQ — Arch Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $0.00m
- $9.36m
- $0.08m
Annual income statement for Arch Therapeutics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | C2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.012 | 0.016 | 0.076 |
| Cost of Revenue | |||||
| Gross Profit | — | 0 | -0.015 | -0.036 | -0.002 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.37 | 5.35 | 6.21 | 5.72 | 5.12 |
| Operating Profit | -6.37 | -5.35 | -6.2 | -5.71 | -5.04 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -4.55 | -4.69 | -6.24 | -5.28 | -6.98 |
| Net Income After Taxes | -4.55 | -4.69 | -6.24 | -5.28 | -6.98 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.55 | -4.69 | -6.24 | -5.28 | -6.98 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.55 | -4.69 | -6.24 | -5.28 | -6.98 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.47 | -4.99 | -5.84 | -4.4 | -2.27 |